IN2014DN09092A - - Google Patents

Info

Publication number
IN2014DN09092A
IN2014DN09092A IN9092DEN2014A IN2014DN09092A IN 2014DN09092 A IN2014DN09092 A IN 2014DN09092A IN 9092DEN2014 A IN9092DEN2014 A IN 9092DEN2014A IN 2014DN09092 A IN2014DN09092 A IN 2014DN09092A
Authority
IN
India
Prior art keywords
infarction
medicinal composition
treating
active ingredient
hsa mir
Prior art date
Application number
Other languages
English (en)
Inventor
Shinya Minatoguchi
Yukihiro Akao
Original Assignee
Univ Gifu
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Gifu, Otsuka Pharma Co Ltd filed Critical Univ Gifu
Publication of IN2014DN09092A publication Critical patent/IN2014DN09092A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN9092DEN2014 2012-04-12 2013-04-12 IN2014DN09092A (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012090873 2012-04-12
PCT/JP2013/061118 WO2013154192A1 (ja) 2012-04-12 2013-04-12 梗塞治療用医薬組成物

Publications (1)

Publication Number Publication Date
IN2014DN09092A true IN2014DN09092A (pl) 2015-05-22

Family

ID=49327750

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9092DEN2014 IN2014DN09092A (pl) 2012-04-12 2013-04-12

Country Status (8)

Country Link
US (1) US20150064237A1 (pl)
EP (1) EP2837389A1 (pl)
JP (1) JPWO2013154192A1 (pl)
KR (1) KR20150002781A (pl)
CN (1) CN104470543A (pl)
CA (1) CA2870248A1 (pl)
IN (1) IN2014DN09092A (pl)
WO (1) WO2013154192A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7445997B2 (ja) 2020-06-08 2024-03-08 国立大学法人東海国立大学機構 マイクロrnaの慢性期心機能改善治療への利用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539276A (ja) * 2005-04-27 2008-11-13 ユニバーシティ オブ フロリダ リサーチ ファウンデーション,インコーポレイティド ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法
CN102083980A (zh) * 2008-02-21 2011-06-01 得克萨斯系统大学董事会 调节平滑肌增殖和分化的微小rna及其用途
US8927506B2 (en) * 2008-07-11 2015-01-06 Board Of Regents, The University Of Texas System Acetates of 2-deoxy monosaccharides with anticancer activity

Also Published As

Publication number Publication date
CN104470543A (zh) 2015-03-25
JPWO2013154192A1 (ja) 2015-12-21
US20150064237A1 (en) 2015-03-05
WO2013154192A1 (ja) 2013-10-17
CA2870248A1 (en) 2013-10-17
KR20150002781A (ko) 2015-01-07
EP2837389A1 (en) 2015-02-18

Similar Documents

Publication Publication Date Title
WO2014062720A3 (en) Methods of treating cancer
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
HK1205941A1 (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate
IN2014DN11099A (pl)
IN2015DN00376A (pl)
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
MY177994A (en) Therapeutically active compounds and their methods of use
IN2014DN10386A (pl)
SG195110A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
IL266623A (en) A pharmaceutical preparation for use in the therapeutic treatment of cancer and complications of cancer
CA3292080A1 (en) Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
CA3010708A1 (en) Methods of administering hepcidin
HK1209672A1 (en) Treatment of multiple sclerosis with combination of laquinimod and fampridine
MY200803A (en) Mpo inhibitors for use in medicine
WO2015148971A3 (en) Method for detecting or treating triple negative breast cancer
WO2015063613A3 (en) Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
MX2020006228A (es) Tratamientos combinados que comprenden la administración de 1h-pirazolo[4,3-b]piridinas.
GB2533235A (en) Vesicles
GEP20247606B (en) Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
IN2014DN09437A (pl)
HK1200731A1 (en) Diethyl- [6- (4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl) - naphthalen-2-yl-methyl] -ammonium chloride for use in the treatment of muscular dystrophy
PT3937948T (pt) Fitoecdisonas e seus derivados para utilização no tratamento de doenças neuromusculares